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Cancer is among the leading causes of deaths in Kenya after infectious and cardiovascular diseases. 
Among the various forms of cancer, breast cancer accounts for a significant percentage of all new 
cancer incidences in the country and has a high mortality rate. On a global level, breast cancer is 
considered the most common cancer. Treatment methods employed vary from patient to patient 
due to factors such as the stage, age, and health. Treatment methods such as surgery, radiotherapy, 
chemotherapy or a combination of all have been used all to varying degrees of success and are not 
always efficient. However, these modalities have been employed successfully when the disease is 
detected early. 
This research applied deep neural networks coupled with genetic algorithms to build a learning 
model that evaluated the biomarkers obtained from cell-free DNA. The model was able to predict 
progression of breast cancer. The research, in addition, employed an agile, data-driven 
methodology due to its recursive nature producing a model with a higher degree of accuracy and 
specificity. The model developed was able to attain an accuracy of 94% in predicting breast cancer 
progression. 
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Chapter 1: Introduction 
1.1 Background  
Cancer is a disease that is characterized by the continuous growth and abnormal uncontrollable 
division of body cells thereby forming a tumour. The unusual growth can then invade other parts 
and organs of the host’s body eventually leading to death (Cancer, 2018). There are different types 
of cancer such as prostate, cervical, lung, breast, stomach and many others that afflict different 
organs of the human body. Cancer is among the leading causes of death in the world accounting 
for 9.6 million deaths with 70% of the cancer-related deaths occurring in low- and middle-income 
countries. The prevalence of cancer in low- and middle- income countries has been exacerbated 
by the risk factors present in these countries such as excessive consumption of alcohol, tobacco 
use, genetic predispositions, and infections. 
Breast cancer is the most commonly occurring cancer in women and the second most commonly 
occurring cancer overall according to the world cancer research fund international. It is estimated 
that there are 2 million cases worldwide yearly (Breast Cancer Statistics, 2018). In Kenya, 
evidence shows that cancer is third leading cause of death after infectious diseases and 
cardiovascular conditions accounting for 28,000 and an average of 37,000 new cases of cancer 
(Kenya National Strategy for the Prevention and Control Non-Communicable Diseases 2015-
2020, 2015). The situation is getting worse as the number of new cases increase yearly. This 
necessitates a proactive approach to detection, monitoring and treatment of cancer. 
According to Shulman et al., (2010), more than half of the incident cases of breast cancer occur in 
developing countries. A high proportion of these cases are detected in late stages due to the 
inadequate facilities, lack of awareness and access to treatment. Additionally, the facilities required 
are expensive and therefore, in the developing countries, there is a dearth of affordable, high-
quality treatment options thereby exacerbating the breast cancer burden in the countries. However, 
these developing countries realize the urgency of the disease and most countries have strategies to 
aid in curbing the disease. 
There is an emphasis on early detection as cancer can be treated successfully when detected early. 





recurrence. Well developed monitoring mechanisms thereby become vital in the fight against 
cancer. Constant monitoring can identify recurrence, metastasis and even resistance to treatment. 
In addition, accountability of artificial intelligence used in healthcare is a major problem (Panch, 
Szolovits, & Atun, 2018). Deep learning methods have hidden layers through which data is 
processed to derive an inference. The operations of these layers are abstracted from the users and 
the results obtained as a result are not describable to a human observer. This research tackled this 
issue by employing the LIME (Local Interpretable Model-agnostic Explanations) model. 
 
1.2 Problem Statement 
Current breast cancer monitoring methods employed are invasive. Monitoring response to 
treatment is not always efficient due to the nature of the methods employed and their limitations 
that lead to extended periods of time between testing and clinical application of results (Sobhani, 
Generali, Zanconati, Bortul, & Scaggiante, 2018). Predictions rely on data retrieved as a result of 
the monitoring methods used. This research employed an approach to predicting breast cancer 
progression by combining critical biomarkers of breast cancer derived from liquid biopsies that 
enumerated circulating cell-free DNA (cfDNA) and other breast cancer biomarkers. The 
concentration of cfDNA is higher in cancer patients and thus is a useful biomarker in monitoring 
cancer and as a result in predicting progression. 
1.3 Aim 
The aim of this research was to develop a model for  analyzing the concentration of cfDNA at 








1.4 Specific Objectives 
(i) To review the application of machine learning in the prediction of cancer 
progression 
(ii) To analyze biomarkers used from liquid biopsies to predict disease progression 
(iii) To review the techniques used in monitoring cancer progression 
(iv) To review the use of cfDNA in cancer detection and predicting progression 
(v) To develop and test the model 
1.5 Research Questions 
(i) To determine progression of breast cancer, what are the methods employed in 
monitoring breast cancer? 
(ii) How is breast cancer progression determined? 
(iii) What are the biomarkers used to determine progression of breast cancer? 
(iv) What machine learning techniques have been used to determine progression of 
breast cancer? 
1.6 Justification 
According to Cancer (2018), breast cancer accounts for approximately 15% of all cancer deaths 
among women. Most of these deaths happen in the developing world. The high mortality rate 
coupled with the heterogeneity of breast cancer tumours necessitates better monitoring. 
Consequently, the ability to predict, more accurately,  how breast cancer will progress will enable 
further breakthroughs in cancer treatment research. This research therefore builds on previous 
studies by exploring the co-relation of the different biomarkers in plasma at different cancer stages 
and derive inferences about cancer progression. Use of predictive analytics used in conjunction 
with the doctor’s skills and input can lead to improved medical care and this research therefore 
looks to provide a platform to be used by medical professionals in the field of cancer to be able to 





This research took advantage of previous studies that tracked the concentration of cfDNA, drawn 
from liquid biopsies, as well as genetic expressions of cancer genes, to come up with an adaptive, 
learning model that can be used to predict breast cancer progression with a higher degree of 
accuracy. 
1.7 Scope and Limitation 
This study is limited to working with prior collected data that has been pre-processed. In addition, 
the study only looked at the co-relation between biomarkers at different stages and seek to derive 
an inference. Lastly, even though the study can be used to monitor the efficiency of treatment 
employed, monitoring breast cancer and treatment modalities of breast cancer are outside the scope 






Chapter 2: Literature Review 
2.1 Introduction 
This chapter covers the importance of monitoring cancer progression and the methods employed. 
In addition, applications of machine learning that have been employed in predicting cancer, 
particularly breast cancer, are further analyzed as well as their shortcomings. Lastly, a conceptual 
framework that will govern this research will be presented. 
2.2 Cancer Monitoring Methods 
After a diagnosis of cancer, monitoring becomes a crucial p rocess. Depending on the stage, health 
and wishes of the patient, treatment can commence. The most common cancer treatment methods 
in the treatment of cancer include surgery such as cryosurgery, laser surgery, radiotherapy, 
chemotherapy or a combination of the treatment options (Types of Cancer Treatment, 2020). 
Monitoring, therefore, becomes important as the patients’ treatment response can be monitored 
and potential side effects can be observed and addressed. Furthermore, disease progression can be 
tracked, and treatment can be administered accordingly. Most importantly, monitoring helps to 
ensure the patients’ health or quality of life. 
The key components monitored include the organs affected, the severity of the symptoms, and the 
side effects of the treatment administered. Ethical considerations in cancer treatment and 
monitoring need to be observed and patients need to be given a choice and make decisions. 
Therefore, treatment and monitoring methods employed are dependent on the patient. 
There exist different methods employed in monitoring cancer. Conventional methods and non-
conventional. These methods are characterized by how widely used they are. Conventional 
methods have been widely used and include methods such as CT (Computed Tomography) scan, 
PET (Positron Emission Tomography) scans while non-conventional methods are relatively newer 
ways of monitoring cancer such as liquid biopsy. 
2.3 Conventional Cancer Monitoring Methods 
Standard cancer monitoring methods which are widely accepted by the medical research 
community are in existence and widely used. CT scans use X-rays that generate detailed images 
and can aid in monitoring the spread of cancer to other organs. During a CT scan X-ray, the 





information than static X-rays (Computed Tomography (CT), 2020).The CT scans can help 
determine whether the tumour is growing bigger or getting smaller. The tumours can be identified 
even before the symptoms have manifested in the patient’s body.  
PET scans can be used to emphasize the output obtained from the CT scan. PET/CT scan is a type 
of nuclear medicine imaging which measures the metabolic activity of cells in body organs. The 
scan measures the photons that are produced as a result of the annihilation when electrons and 
positrons in the body combine producing energy. The information obtained is thus used to create 
images of internal organs. Variations which indicate patient disease state can be detected. This 
forms the basis of progress monitoring (Nuclear medicine, 2020). 
Mammogram, ultrasound and Magnetic Resonance Imaging (MRI) are also used in cancer 
monitoring. MRI uses an intense magnetic field during the examination process. It produces 
detailed three-dimensional images. The process takes forty- five to sixty minutes per body part 
(Magnetic Resonance Imaging (MRI), 2020). During this time, magnets are open on both ends and 
the patient is expected to lay still. The radiologist can communicate with the patient during the 
session to instruct about any discomfort and other related concerns. 
Despite the success of these conventional imaging approaches, they have limitations. First, they 
cannot tell if the detected abnormality is a cancer tumour or just a normal scar related tissue. 
Secondly, they are pivoted around clinical morphology metric where tumour size, shape or colour 
is measured before, during and after therapy. Thirdly, the response to treatment of patients is not 
efficiently measured as the size and shape of the tumour are not adequate metrics. Lastly, the 
output of these techniques is often obtained late during treatment. 
2.4 Non-conventional Cancer Monitoring Methods 
Non-conventional cancer monitoring methods include biopsy, diffusion-weighted MRI and mobile 
symptom monitoring. 
2.4.1 Biopsy 
A biopsy is a technique used to diagnose and monitor cancer. Many argue that it is a sure way of 
diagnosing cancer. However, this argument fall short as the information obtained from the biopsy 
is a snap-shot of a tumour and hence does not capture the heterogeneity of tumours and can be 





2013). The process comprises the removal of physical body tissue for examination followed by 
imaging using specialised medical devices such as microscopes. The cells are extracted from the 
sample using a needle and examined for tumours. The procedure varies among patients based on 
the type and location of the tumour. Apart from diagnosis, it has the potential for monitoring of 
the treatment response through analysis of genes related to tumours. Crowley et al. (2013), reported 
that biopsy can be used in determining the disease progression and patient response to the treatment 
method. 
The biopsy process has some challenges associated with it. Firstly, it is invasive. The process is 
painful for the patient. Secondly, surgical complications exacerbate the chances of cancer spread 
to other parts of the body. These limitations have significantly inhibited its adoption and as a result, 
other non-invasive options such as liquid biopsy have gotten much attention by the medical 
community. 
2.4.2 Liquid Biopsy 
Liquid biopsy is a non-invasive approach used to detect and monitor cancer. It involves the use of 
simple blood tests to detect cancer agents such as circulating cell-free DNA (cfDNA) and 
Circulating Tumour Cells in blood. The latter and former have proven to bear a direct correlation 
with the presence of tumour cells. Saliva, urine, plasma, cerebrospinal and seminal plasma are 
other biological fluid variations that can be used (Di Meo, Bartlett, Cheng, Pasic, & Yousef, 2017). 
In contrast to biopsy and conventional imaging methods which are dependent on cell tissue and 
images respectively, liquid biopsy is a tumour marker monitoring method. A blood sample can be 
used to determine disease and tumour progression. This method overcomes some of the limitations 
of tissue-based biopsy by allowing for the screening biomarkers which are secreted by tumour 
cells into the blood. Crowley et al., (2018), reports that liquid biopsy can provide the genetic 
landscape of all cancerous lesions as well as the opportunity to track genomic evolution. In 
addition, tracking tumour-associated genes by use of blood can be used to evaluate the presence 
of residual disease, recurrence, relapse and resistance. The non-invasive nature of liquid biopsy 
allows for continuous monitoring over extended periods of time.  
The general liquid biopsy process is composed of a collection of blood samples, preparation, 





requires 3 ml of blood fluid for plasma preparation. This should be carried out within 5 - 6 hours 
of withdrawal. The collection is done using tube cleansed with an anticoagulant such as 
ethylenediaminetetraacetic acid. Cells are thereafter extracted through centrifugation followed by 
plasma removal after a successful blood clot. The DNA related to tumours are then extracted using 
the recommended medical kits such as Maxwell RSC (MR), ccfDNA Plasma, Nucleic Acid 
Isolation, MagNA Pure Compact (MPC), QIAamp Circulating Nucleic Acid (QCNA). Currently, 
there is no agreed extraction method, but each has associated sensitivity and accuracy issues. 
Additionally, the method of extraction of cfDNA can also affect the DNA yield and should be 
considered in the analysis (Pérez-Barrios, et al., 2016). 
2.5 cfDNA in Cancer Treatment and Monitoring 
Cell-free DNA consists of DNA fragments released after cell death processes from both normal 
cells and tumour cells (Sobhani et al., 2018). Tumour cells release DNA via multiple mechanisms 
allowing detection of cancer-associated genetic alterations (Zhang, et al., 2018). Cancer patients, 
therefore, have a higher cell turnover than normal patients and thus have a higher concentration of 
cfDNA. 
Sobhani et al., (2018) opine that cfDNA obtained from plasma through liquid biopsy tackles the 
problem of searching for tumour DNA mutations of targeted genes making it effective in 
monitoring cancer. Obonyo (2018) focused on CTC (circulating tumour cells) obtained from liquid 
biopsies. However, this approach is limited because CTCs do not always indicate genetically 
cancerous cells. Thus, cfDNA was used in this study as it is theoretically representative of all 
tumours and can differentiate between signals from non-cancer and pre-cancerous cells (Sobhani 
et al., 2018). 
Sobhani et al., (2018) determined there is a possibility of monitoring breast cancer by use of 
cfDNA as shown in figure 1 either qualitatively by looking at mutations or quantitatively. 
However, there are limitations to both approaches. Qualitative studies done of the mutations only 
represent approximately 40% of breast cancer patients while quantitative studies of cfDNa in 
breast cancer patients, cfDNA values can be impacted by viruses or infections which can increase 






Figure 2.1: Monitoring breast cancer from cfDNA 
Nonetheless, cfDNA presents great advantages in the context of breast cancer monitoring. The fact 
that it can be monitored repeatedly, without having an invasive procedure done on the patient, even 
after the primary tumour has been removed can aid in the prediction of recurrence (Cheng, et al., 
2017). Crowley et al., (2018), reported that monitoring of tumour-associated genetic aberrations 
through cfDNA obtained from blood can be used to detect the émergence of resistant cancer cells 





2.6 Machine Learning Approach to Predicting Breast Cancer 
2.6.1 The classification prediction problem 
Classification has been commonly used in previous breast cancer prediction studies to determine 
whether breast cancer is present or not, whether a tumor is benign or malignant and thus their 
diagnostic capabilities can prove to be very effective (Amrane, Oukid, Gagaoua, & Ensari, 2018). 
Given a training data set, the classification prediction problem is the approximation of a mapping 
function from the input variables contained in the training data set to output variables. Thereby, a 
class or category is predicted for a given observation (Brownlee, 2019). 
The learning algorithm thus learns a classification function from the training data set that maps the 
observation(s) to a given category. The classification function is then able to predict previously 
unseen observations to their respective categories. 
2.6.2 Feature Engineering 
Feature engineering is a critical step when preparing data with high-dimensionality. It transforms 
the raw data into features that can be selected that better represent the problem under study. The 
resultant data is thus suitable for modeling as the computational complexity is reduced and gives 
rise to an improved model performance (Rençberoğlu, 2019). Principal component analysis and 
genetic algorithms are two methods that can be used to reduce the dimensionality of data. 
2.6.2.1 Principal Component Analysis 
Principal component analysis transforms large data sets into smaller data sets by identifying the 
correlations and patterns while still retaining as much of the variability of the data, thereby 
preserving most of the data’s valuable information. The reduction in the number of variables taken 
into account for analysis results in faster models due to the reduction in computational complexity 
(Howley, Madden, O'Connell, & Ryder, 2006). In breast cancer micro array data, principal 
components can be used to uncover groups of genes that express together and can be useful in 
breast cancer prediction studies (Bair, Hastie, Debashis, & Tibshirani, 2006). 
2.6.2.2 Genetic Algorithms 
This is an optimization approach with the goal of simulating evolutionary processes of a living 





through conventional techniques (Niazi & Leardi, 2012). The quality of the possible solutions 
obtained is evaluated by a fitness solution that is specific to the problem under study. Genetic 
algorithms thus rely on operators such as crossover, mutation and selection. 
 
2.7 Machine Learning Algorithms 
An algorithm is a systematic set of steps taken by a computer program to process a given set of 
input. This study used genetic algorithms and a deep learning optimized with the stochastic 
gradient descent algorithm. 
Artificial neural networks provide a generalized method for learning different valued functions 
from examples. The motivation behind the working of these networks has been from observing 
biological systems (Mitchell, 1997). The general structure of the artificial neural networks is inputs 
are sent to the hidden layers where the processing is done and output(s) is given. This 3-layer 
structure is referred to as a multi-layered perceptron as shown in Figure 2.2 (Kim & Kim, 2019). 
Neural networks generally consist of connected nodes called neurons whose weights change as the 
artificial neural network learns. The first component of the neurons is the linear function whose 
output is the sum of the inputs each multiplied by the weights. The linear function would be 
expressed as shown in equation 2.1 for input x1, x2, x3, and output z (Bernico, 2018). 
 
Equation 2.1: Neuron linear function 






Figure 2.2: Multi-Layer Perceptron 
Deep learning which is a form of Artificial Neural Networks is characterized by a neural network 
made up of multiple hidden layers (Bernico, 2018). Figure 2.4 depicts the structure of a deep 
learning neural network. Recurrent neural networks is an example of deep learning that was used 
in this research to come up with the predicted outputs. 
 





2.7.1 Recurrent Neural Network 
Recurrent neural networks (RNN) are a set of neural networks that allows previous output to be 
used as input while having hidden layers. It can be represented as shown in Figure 2.2. This 
algorithm is advantageous as it affords the possibility of processing input of any length. In addition, 
it takes account of historical information and hence can be useful in processing data where 
historical information is vital in predicting future characteristics. 
 
Figure 2.4: Recurrent Neural Network 
Recurrent Neural Networks rely on memorization of the information in the sequence. Due to this, 
it may have potential pitfalls such as being memory-intensive. To reduce the error involved with 
using the model, backpropagation through time is used and is done at each stage (Amidi & Amidi, 
n.d). Backpropagation employs gradient descent to attempt to minimize the squared error between 
the model output values and the targeted values. It can be represented as shown in equation 2.1 
where E represents the sum of errors over the output units (Mitchell, 1997). 
 
Equation 2.2: Backpropagation 
The gradient descent is the backbone of the backpropagation algorithms as it can serve as the basis 
of learning algorithms that work through heterogeneous data spaces. The gradient descent is hence 





2.7.2 Random Forest 
Random forests is a classification algorithm that consists of many decision trees thus creating 
correlated trees. Due to its simplicity and diversity it can be used for both classification and 
regression tasks. While growing the trees, random forest adds additional randomness by searching 
for the best feature among a random subset of trees. Lastly, after the random selection of trees and 
features, the final prediction is determined by majority voting or averages (Ahmad & Yusoff, 
2013). Figure 2.3 depicts an example of random forest with two trees. 
 
Figure 2.5: Random Forest 
2.7.3 Decision Trees 
Decision trees are used in classification and regression training and are determined by iteratively 
partitioning the input from a root node to multiple branch nodes. The root node is the first division 
from which other nodes are created. The division is based on condition tests such as the gini index, 
entropy or the classification error that determine the nodes the input are split into. This recursive 





Andrade, & Silva, 2016). The result of a decision tree is a set of rules that can be used to make 
predictions. Figure 2.4 depicts the tree structure. 
 
Figure 2.6: Decision Tree 
Decision trees have been used in breast cancer studies to predict recurrence and also predict 
patients’ risk of cancer. Decision tree model has been employed in gene selection and classification 
on high-dimensional microarray data and used to predict risk of breast cancer to a high degree of 
accuracy (Hamim, El Moudden, Moutachaouik, & Hain, 2020). 
2.7.4 Naïve Bayes 
In making a decision, the Naive Bayes classifier takes into account the probability distributions of 
patterns in each class of the data set. The assumption it makes is that there exists a probabilistic 
relationship between the features and the class. Given  a sample S and class C, the learning process 
involves determining the probability P(C |S). This is the probability that the class belongs to the 
given sample. The posterior probability P(S |C) is the probability of observing the sample S given 
the class C (Abreu, Santos, Abreu, Andrade, & Silva, 2016). Using Bayes theorem, the likelihood 












2.7.5 Local Interpretable Model-Agnostic Explanations (LIME) 
Ribeiro, Singh, and Guestrin (2016) argued that explaining predictions is a vital aspect of getting 
humans to trust machine learning models and use them effectively. Given that deep learning 
models operate as a black box, with the operations of the hidden layers not known, effectively 
adopting them is a challenge especially in exact fields such as medicine. They, therefore, proposed 
a model that could explain the predictions of any classifier by approximating it with an 
interpretable model. The model can be illustrated as shown in Figure 2.5. In the representation, the 
model predicts flu from the inputs and LIME highlights the factors that led to the prediction. The 
doctor decides whether to trust the prediction. 
LIME can be used in breast cancer prediction studies to aid in acceptance of the models generated 
as well as their validation by oncologists. In addition, the models will benefit from the explanations 
as errors in the predictions can be highlighted and improved upon. 
 
Figure 2.7: LIME Representation Adapted from (Ribeiro, Singh, & Guestrin, 2016) 
 
2.8 Related work 
Numerous machine learning algorithms have been employed in numerous studies on breast cancer. 
Some studies have focused on treatment, monitoring, prediction of recurrence, metastasis, disease 
progression and the survival rate.  
Oketch (2018) used circulating tumors to monitor breast cancer progression. The study focused on 





networks to identify the circulating tumor cells. This study was limited to monitoring and thus 
predictive capabilities were not explored. 
Using serum biomarkers determined that the random forest model, with an accuracy of 75%, was 
the optimal algorithm to predict breast cancer metastasis 3 months in advance. By predicting 
metastasis early, the study may be helpful in early detection and early treatment (Tseng, et al., 
2019). However, the study only evaluated one gene namely; HER2. This presents a limitation as 
better results can be obtained through the evaluation of a combination of genes. 
Some studies automated the process by which recurrences were identified. Using natural language 
processing, doctors’ progress notes were automated (Zeng, et al., 2018). The support vector 
machine was determined to have the highest accuracy. Nonetheless, this approach does not really 
predict progression nor provide further insights into breast cancer. 
Other studies showed how vital constantly monitoring cancer patients is. A smartphone chatbot 
application to monitor older cancer patients was used and timely interventions were made to the 
patients under the study ensuring care was provided promptly (Piau, Crissey, Brechemier, Balardy, 
& Nourhashemi, 2019). 
Moreover, other studies have recognised the importance of having explanations for machine 
learning based predictions. Case based reasoning approach to explaining predictions is one such 
example (Lamy, Sekar, Guezennec, Bouaud, & Séroussi, 2019). The cases were retrieved from the 
database based on the similarity of the query received. However, the drawback of this approach 
was that the accuracy scores received were approximately 80%.  
This study builds upon other studies on employing machine learning algorithms to breast cancer 
by predicting how breast cancer will progress by comparing the accuracy obtained by different 





2.9 Conceptual Framework 
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Chapter 3: Research Methodology 
3.1 Introduction 
In this chapter, the research methodology used is outlined. The aspects covered include the 
approaches to data collection, processing, the system development methodology as well as 
perspectives on research design, research quality and the ethical considerations adhered to. 
3.2 Research Design 
Research design is a strategic, systematic, coherent and reasonable way that incorporates all 
components of the research to completely address the problem under study (Oduor, 2017). 
Therefore, quality research design implies the application of a well-structured methodology in the 
collection, measurement and analysis of data to arrive at solutions to the research questions. To 
arrive at the solutions to the research questions, secondary data analysis was done. This approach 
was chosen due to the time constraints in completing the research within the set timelines. In 
addition, due to the specialized data requirements, this approach was the most feasible. 
This research is applied research. The aim of this research is to find a solution that can be used by 
society to alleviate the problems faced. It is for this reason that it is applied research due to the 
envisaged application of knowledge obtained to solve problems in society. 
3.3 Model Development 
The model is an artificial neural network that will be developed as follows: 
I. Obtaining data 
II. Processing of data 
III. Extraction of features 
IV. Development of the model 
V. Validation of the model 
3.3.1 Data Acquisition 
The data was obtained from the publicly available database of the European Biomedical Institute. 
The data was retrieved from the Array Express database under the number E-MTAB-624. The 
primary collectors of the data that made the data available publicly adhered to the Declaration of 





The data is in the form of .CEL files which were downloaded as numerous zip files due to the size 
of the data. The data consists of information of 65 breast cancer patients and 8 control patients. Of 
the 65 patients, 15 had a recent diagnosis of breast cancer and 50 had been receiving treatment 
over a 3 year period (Shaw, et al., 2012). The data which is genotyped by array, thus consisted of 
the patients’ clinical history, their individual genetic characteristics and the disease state. The 
specific variables in the dataset include the type of surgery undergone by the patients, tumor grades 
and size, menopausal status and genes. The original work was based on use of CfDNA to infer 
dormancy as opposed to progression of cancer that this paper focuses on. Table 3.1 shows the 
characteristics of the data obtained showing the number of patients with different tumour sizes and 
grade and at different stages of treatment. 
Table 3.1: Data Characteristics 
 Pre-treatment 
primary breast cancer 




Tumour Size    
T1 43 9 10 
T2 24 8 7 
T3 8 1 3 
T4 0 0 0 
Unknown 3 4 10 
Tumour Grade    
1 5 3 0 
2 31 16 17 
3 41 2 9 
Unknown 1 1 4 
3.3.2 Data Processing 
The data is in .CEL file format, therefore, to be able to analyse the data, pre-processing of the data 
using the dChip which is an open source program was vital. In addition, since the data contains 
over 200 genomic profiles, factor analysis was done to determine the combination of features that 





The data was processed by performing normalization and summarization. The output of this 
process was a .txt file that was used in training and testing of the model. The file contained genes 
and microarrays that were subjected to further analysis. 
On further analysis of the data, data from the 8 control patients were excluded from further 
processing. The remaining data was retrieved and contained 57 different attributes that included 
the ER status, disease free months, HER status, tumor stage, size of the tumor, time between 
diagnoses, time to death, among others for all the patients under study. 
3.3.3 Model Development 
The model was developed using Weka which is an open source tool. It was chosen due to its 
capability to develop recurrent neural networks in addition to other neural networks.  
The deepLearning4j library by Weka was used to develop a deep learning model from the 
processed data. The results from the deep learning and other algorithms used to predict progression 
of breast cancer were used to compare and determine which algorithm is the most accurate for the 
study. 
The model was developed by first, splitting the dataset into three: 60% training, 20% validation 
and 20% testing. The split into three was intended to make the model better at generalizing with 
data it has yet to see. Due to the vast number of features in the dataset, feature extraction was 
performed on the training dataset by employing methods such as the Principal Component 
Analysis technique and Genetic Algorithms to identify patterns in the data. The intention of 
deploying these feature extraction techniques was to decrease the features to be studied by either 
eliminating some or combining some features into one or reducing redundant features in the 
dataset. The data was then fed into learning algorithms and comparisons done on the accuracy and 
specificity of the models. The model identified was then validated and tested. 
3.3.4 Model Validation 
The model was evaluated using the Root Mean Squared Error (RMSE), Mean Absolute Error 
(MAE), Relative Absolute    Error (RAE), Root Relative Squared Error (RRSE) and the Kappa 






3.4 System Development Methodology 
The system development methodology is a structured framework with organized principles and 
methods that are used to deliver a system (Okonkwo & Huisman, 2018). This research utilizes an 
agile approach to the data-driven methodology. 
The data-driven methodology is based on computational intelligence and machine learning and 
therefore does not necessitate explicit knowledge of the physical behaviour of the system. It 
involves the analysis of input, internal and output variables and finding connections between the 
variables (Solomatine, See, & Abrahart, 2009). Figure 3.1 depicts the methodology. 
 
 
Figure 3.1: Data-driven modelling(Adapted from (Solomatine, See, & Abrahart, 2009)) 
Agile software development was employed due to its iterative nature. The basic principles of this 
methodology are working code and working together (Highsmith & Cockburn, 2001). The 
emphasis on iteration and working code was observed in this research by continuously improving 
the model to achieve a higher model accuracy. Working together entailed constant interaction with 
the stakeholders of this research thereby improving the overall quality of the research and the 
output. 
3.5 Research Quality 
The researcher intends to provide quality research by ensuring that all materials accessed and used 





literature sources from reputable sources. Lastly, to guarantee quality research work, the researcher 
validated his findings by use of empirical validation methods for neural networks to ensure a higher 
degree of acceptability of the model. 
3.6 Ethical Considerations 
This research utilized publicly available data obtained from the European Bioinformatics Institute. 
The institute has ensured that data that is publicly available only contains de-identified data. Use 
of the data was credited in this research to the owners of the data. The dataset used contains only 
data such as gender, age, tumor type, grade, type of procedure, the status of receptor hormones and 
gene biomarkers which cannot be used to identify a patient and hence ensuring their privacy and 
confidentiality. 
In addition, the researcher obtained ethical review from an Independent Ethical Review Board to 
aid in ensuring that the safety and rights of potential research participants are safeguarded as well 






Chapter 4: System Design and Architecture 
4.1 Introduction 
This section outlines the architecture of the developed prediction model for breast cancer 
progression. The architecture build up on the conceptual model developed in Figure 2.5. This 
section covers the requirements that need to be satisfied, the components of the developed system, 
the interaction between the end user and the developed system. In addition, it covers the 
interactions between the components of the developed model. Use case diagrams, sequence 
diagrams, context diagrams as well as data flow diagrams were used to model the system. 
4.2 Requirements Analysis 
The requirements will be broken down into five namely: Functional requirements, non-functional 
requirements, usability requirements, reliability requirements and performance requirements. 
4.2.1 Functional Requirements 
i. The system should allow the user to input data as CSV, TSV or XLS files. All other forms 
should be rejected. 
ii. The system should extract the PR, ER and HER2 statuses. 
iii. The system should be able to predict progression of tumor by use of deep learning. 
iv. The predicted progression status should be valid based on the input supplied from the user 
v. The system should provide an explanation on how the progression was arrived at 
4.2.2 Non-functional Requirements 
i. The system should be easy to re-train and adjust the weights 
ii. The system should be able to robustly generalize new instances and avoid overfitting 
iii. The system should be secure to avoid unauthorized changes to the model parameters 
iv. The system should have persistent weight storage to avoid re-training every time a 
prediction is done 
4.2.3 Usability Requirements 
The system is intended to be used in a clinical setting; hospitals and clinics. The system should 
therefore be simple to use. It should also be straightforward to ensure that it can be easily accepted 
by the users. The system should also provide accurate predictions and explanations to the 





4.2.4 Reliability Requirements 
i. The system should always interface with the existing database containing clinical 
information 
ii. The administrator should be able to correctly restore the system in the occurrence of a 
failure 
4.3 Architecture 
The system architecture gives a generalized layout of the breast cancer progression prediction 
prototype and its individual components as shown in Figure 4.1. The process begins by extracting 
data from the database that is supplied by the user. The data is then pre-processed to clean the data, 
detect outliers as well as handle missing values. The data is then fed to the feature extracter where 
the suitable features are determined for further processing. The data with the extracted features is 






Figure 4.1: System Architecture 
4.4 Use Case Diagram 
The use case diagram is used to depict the interaction between actors and the system. Figure 4.2 






Figure 4.2: Breast Cancer Progression Prediction Use Case 
4.5 System Sequence Diagram 
The system sequence diagram illustrates how the primary user and the system interact. Figure 4.3 
illustrates this interaction. The oncologist will first initiate the process of prediction. He/She will 
load the data that they intend to get prediction results for and then end the prediction. The system 





the oncologist will ask for an explanation of how the prediction was arrived at and the system will 
output the explanation. 
 
Figure 4.3: System Sequence Diagram 
 
4.6 Sequence Diagram 
The sequence diagram shown in Figure 4.4 shows the sequence of interactions between the user 
and the internal components of the system. The data uploaded is first processed and the processed 
data undergoes feature extraction. The data is then split into training and test cases and fed into the 
artificial neural network to create the model. The system then performs the prediction and sends it 
to the oncologist with the percentage accuracy. The oncologist then asks for an explanation to the 






Figure 4.4: Sequence Diagram 
4.7 Flow Chart Diagram 
The process flow of how the training model is obtained is shown in Figure 4.5. Patient data is 
entered and the data is then pre-processed. The data is then tested based on the existing generated 
model based on the predefined number of epochs (stopping condition). If the model is not optimal, 
then it checks if the number of epochs that have to be run while training the model has been met. 
If the number of epochs has been met, the system stops. 
If the number has not been met, the weights are readjusted and a new model is trained. The system 
repeats this process until the stopping condition has been met. The optimal model is them saved 












Chapter 5: Implementation 
5.1 Introduction 
This chapter describes the process of how the prototype was implemented, trained, tested, 
validated and optimized. The process starts by extracting data and normalizing that data. Pre-
processing is then examined and afterwards the model is trained. The model is then validated by 
using the validation data set and it is optimized by adjusting its variables. Once the model is 
optimized, it is tested against the test data and the results evaluated. 
To validate the researcher’s approach, other models were implemented including different ways 
of feature extraction to determine the best configuration combinations. The model with the highest 
accuracy was chosen. 
5.2 Extraction of Data 
Raw data was collected from the European BioInformatics Institute in .CEL format. The raw data 
was extracted by using dChip software. The data had 264 arrays as shown in Figure 5.1 which 
were treated as samples for the study. The data was further normalized and summarized and the 
results saved in .xls format. The data contained 57 variables. Some of the variables included: ER 
Status of the Primary sample, Menopausal Status At Diagnosis, Metastatic Recurrence Time, 
Overall Patient HER2 Status, PR Status of the Primary sample, Time To Death as well as  the 
Tumor stage. 
 







The data was pre-processed by performing normalization. The string values were converted into 
nominal values to be able to train the machine learning model. After normalization, the data was 
divided into three: training set, validation set and test set. The split was as follows: 60% was used 
as the training data set, 20% was used as the validation data set and the remaining 20% as the test 
data set. The data from the control group was excluded from pre-processing and was not considered 
in the eventual generation of the model. The data sets were then saved in .CSV files that would be 
used later in training, validating and testing the model. 
5.4 Training the Model 
Once the data was pre-processed, the model training could proceed. The .CSV training data  file 
was read into the Weka platform. Before the training data was passed into the deep learning 
classifier, feature engineering was performed on it. A genetic search was performed on the data so 
as to select the best subset of attributes that would be used in the classifier to obtain a greater 
accuracy of prediction. The genetic algorithm parameters were configured as shown in Figure 5.2. 
The population size which represented the number of individuals in the training data set was set to 
40. The maxGenerations which was the stopping function was set to 20 signifying that the 






Figure 5.2: Genetic Algorithm Parameters 
Once the feature engineering was completed, the data was sent to the deep learning classifier that 
was provided as part of the Weka DeepLearning package. The classifier was configured with the 
following parameters: 
1. The number of epochs was set to 10. 





3. The output layer was configured by using the Softmax function and the loss 
function used was Mean Squared Error loss function 
The model was then saved so that it can be validated and optimized later. See Figure 5.3 for a 
diagrammatic representation of the process employed in training and saving the model. 
 
Figure 5.3: Training and saving the model 
5.5 Validating the Model 
After the model was trained, the validation data set was used to validate the model. 10-fold cross 
validation was used and the results evaluated. See Figure 5.3 for the results obtained from the 





model was to make predictions. The Relative Absolute Error and Root Relative Absolute Error 
figures depicted that the model was not accurate and had to be optimized for greater accuracy. 
 
Figure 5.4: Cross-Validation results 
5.6 Optimizing the Model 
The model was optimized by using the Stochastic Gradient Descent optimization algorithm. The 
algorithm was chosen as it updates the parameters for each training example and is much faster 







Figure 5.5: Neural network optimization 
 
5.7 Testing the Model 
After the model was optimized, the it was tested against the test data set. Figure 5.4 illustrates the 






Figure 5.6: Test results after Optimization 
 
5.8 Selecting the Model 
The model was selected based on an evaluation from comparing results from different models built 
from different classifiers. The classifiers used included Naïve Bayes and the Jrip (Weka Classifier). 
Table 5.1 represents the different results obtained that led to selecting the best model. 
Table 5.2: Model results 
    Kappa MAE RMSE RAE RRSE 
Naïve Bayes 0.7042 0.0319 0.1548 32.0048% 69.4307 
Jrip 0.4616 0.0681 0.1846 72.713% 85.34% 
Deep 
Learning 






The deep learning model was thus chosen as it gave the best degree of accuracy and model fit as 






Chapter 6: Discussion 
6.1 Introduction 
This chapter highlights the results of the research in light of the objectives set out.  The main 
objective of the research was to create a learning prediction prototype that can predict the 
progression of breast cancer. A deep learning model was created after the dimensionality of the 
data was reduced by use of genetic algorithm. Different models were evaluated and the best model 
with the best performance determined as the deep learning model with genetic algorithms used to 
select the best subset of attributes. 
6.2 Results 
The aim of this experiment was to compare the performance of the deep learning model 
implemented with Principal Components Analysis(PCA) and without any feature engineering. The 
model was then evaluated and optimized and the results of the experiment are summarized in Table 
6.1 
 
Table 6.1 : Performance Comparison 
Classifier Kappa MAE RMSE RAE RRSE 
Deep learning 
without FE 
0.234 0.1806 0.4244 53.4959 % 103.3475 % 
Deep learning 
with PCA 




0.9203 0.0365 0.1037 37.1308% 47.3002% 
 
The results in Table 6.1 show that the deep learning model with genetic algorithm used for feature 
selection performs better than with model with principal components analysis and without across 





6.3 Research Findings 
The research results found out that the deep learning model enhanced with feature selection by use 
of genetic algorithms as the best approach to predicting breast cancer progression. The model was 
able to predict the Tumor stage as well as the time the cancer progresses to become metastatic with 
a 94% degree of accuracy. This degree of accuracy was achieved as a result of combination of 
factors. Firstly, the optimization of the genetic algorithm used as a feature engineering technique. 
Lastly, the combination of the different functions used in the input and output layers of the deep 
learning algorithm coupled with the loss function optimized the model and thus gave a higher 
accuracy of 94% as compared to the other algorithms experimented. The higher Kappa value of 
0.9203 also signifies that the model’s expected output is closer to the observed output signifying 






Chapter 7: Conclusions, Recommendations and Future Work 
7.1 Conclusion 
The main goal of the research was to develop a learning prototype that was able to predict breast 
cancer progression. Breast cancer progression is identified by the either the cancer progressing and 
affecting other parts of the body or moving from one stage to the next. 
Due to the prognostic value of Circulating Cell-free DNA, biomarkers and status of the major 
cancer genes in it were evaluated and used to develop a deep learning model that was able to 
predict the tumor stage, time taken to progress as well as the time taken for metastasis to occur 
with an accuracy of 94% 
Different machine learning algorithms have different theoretical implications based on the data 
under review. As a result, the various experiments with different classifiers and feature selection 
algorithms helped select the best model. 
7.2 Recommendations 
The accuracy of deep learning algorithms is highly dependent on the volume of data being studied. 
This poses a significant challenge especially when performing studies that involve clinical data. 
Secondly, the sensitivity of the data to the collection techniques employed is a major factor to 
consider when performing such studies. Lastly, the researcher proposes further study in use of 
home measures that interface with the doctors and/or care givers with predictive capabilities 
enabled so that medical intervention can be determined in advance of an occurrence requiring one 
(Tonarelli, 2017). 
The researcher, therefore, recommends that such studies be done in close partnership with health 
institutions and/or professionals. This would ensure greater availability of data as well as a better 
understanding of the impact of the tools used in collecting clinical data and how to incorporate 
them in the model. Furthermore, there needs to be greater exploration of the ethical implications 
of using deep learning in a clinical setting and what measures need to be put in place to ensure 





7.3 Future Work 
There is still a tremendous amount of work that needs to be done to understand breast cancer, how 
it progresses and the heterogeneity of tumors associated with it. There is greater need of making 
more data available to researchers in ensuring that breast cancer is understood and eventually a 
cure is developed. 
The data that is widely available is data that has been collected by foreign bodies  for patients who 
are predominantly Caucasian. The researcher proposes further studies to be done on breast cancer 
by employing technologies such as Federated learning where patients can freely share their 
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